Dr. Reddy's Labs Launches Cefixime For Oral Suspension, USP In US

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Cefixime for Oral Suspension, USP in the U.S. market.

The Cefixime for Oral Suspension, USP 100 mg/5mL and 200 mg/5mL is a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, approved by the U.S. Food and Drug Administration.

The Suprax brand and generic had U.S. sales of approximately $50.5 million MAT for the most recent twelve months ending in June 2017 according to IMS Health.

Dr. Reddy's said the Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5mL and 200 mg/5mL after reconstitution. The 100 mg/5 mL strength is available in 50 mL bottles. The 200 mg/5 mL strength is available in 75 mL and 50 mL bottles.

Suprax is a registered trademark of Astellas Pharma Inc. (ALPMY).